Adjuvant Ciprofloxacin for Persistent BK Polyomavirus Infection in Kidney Transplant Recipients

Citation
Arroyo, David, Sindhu Chandran, Parsia A. Vagefi, and David Wojciechowski. 2014. “Adjuvant Ciprofloxacin for Persistent BK Polyomavirus Infection in Kidney Transplant Recipients.” Journal of Transplantation 2014 (1): 107459. doi:10.1155/2014/107459. http://dx.doi.org/10.1155/2014/107459.

Published Version
doi:10.1155/2014/107459

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:13347613

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Clinical Study

Adjuvant Ciprofloxacin for Persistent BK Polyomavirus Infection in Kidney Transplant Recipients

David Arroyo, Sindhu Chandran, Parsia A. Vagefi, and David Wojciechowski

1 Nephrology Department, Hospital General Universitario Gregorio Marañón, C/Doctor Esquerdo 46, 28007 Madrid, Spain
2 Kidney Transplant Service, Division of Nephrology, Department of Medicine, University of California, San Francisco, 400 Parnassus Avenue, Suite A701, San Francisco, CA 94143, USA
3 Transplant Surgery, Massachusetts General Hospital/Harvard Medical School, 55 Fruit Street, White 544, Boston, MA 02114, USA

Correspondence should be addressed to David Wojciechowski; david.wojciechowski@ucsf.edu

Received 25 March 2014; Accepted 24 April 2014; Published 8 May 2014

Academic Editor: Parmjeet Randhawa

Copyright © 2014 David Arroyo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. BK virus (BKV) infection is a common complication following kidney transplantation. Immunosuppression reduction is the cornerstone of treatment while adjuvant drugs have been tried in small uncontrolled studies. We sought to examine our center’s experience with the use of ciprofloxacin in patients with persistent BKV infection.

Methods. Retrospective evaluation of the effect of a 30-day ciprofloxacin course (250 mg twice daily) on BKV infection in kidney transplant recipients who had been diagnosed with BK viruria ≥ 10^6 copies/mL and viremia ≥ 500 copies/mL and in whom the infection did not resolve after immunosuppression reduction and/or treatment with other adjuvant agents. BKV in plasma and urine was evaluated after 3 months following treatment with ciprofloxacin.

Results. Nine kidney transplant recipients received ciprofloxacin at a median of 130 days following the initial reduction in immunosuppression. Three patients showed complete viral clearance and another 3 had a ≥ 50% decrease in plasma viral load. No serious adverse events secondary to ciprofloxacin were reported and no grafts were lost due to BKV up to 1 year after treatment.

Conclusion. Ciprofloxacin may be a useful therapy for persistent BKV infection despite conventional treatment. Randomized trials are required to evaluate the potential benefit of this adjuvant therapy.

1. Introduction

BK polyomavirus (BKV) is a common pathogen of kidney transplant recipients, which can result in impaired graft function and inferior graft survival [1]. Approximately 30%, 11–13%, and 8% of kidney transplant recipients develop BK viruria, viremia, and BK virus associated nephropathy (BKVAN), respectively [1–3]. Graft loss rates have been reported to be as high as 30–50% following a diagnosis of BKVAN [1, 4], although more recent data indicate that with early diagnosis of BK viremia or viruria using regular screening, the majority of patients respond favorably [5]. However, BKV infection continues to have a major impact on graft function with nearly 25% of infected patients showing a sustained increase in serum creatinine of at least 50% compared to that observed at the time of diagnosis [6]. Several donor and recipient risk factors for the development of BKV infection have been identified and of these, a high burden of immunosuppression appears to be the most important [7].

A strategy of immunosuppression reduction is therefore considered the cornerstone of treatment for BKV infection [8], although a uniform standardized protocol has not yet been established [2, 9]. The inability to clear this virus despite a reduction in immunosuppression has led to a variety of additional agents with possible anti-BK activity being utilized as adjuvant therapy including leflunomide, cidofovir, and intravenous immunoglobulin (IVIG) [10]. All of these agents have been reported to be beneficial in anecdotal cases. However, the use of these agents has been mostly limited by pharmacologic and logistical issues. IVIG is expensive, potentially nephrotoxic, and needs to be administered intravenously over several hours. Leflunomide has significant hematologic and hepatic toxicities and requires therapeutic drug monitoring due to variable interpatient
pharmacokinetics, while cidofovir is highly nephrotoxic and appears to have minimal *in vitro* antiviral activity against BKV.

Fluoroquinolones have been reported to display anti-BKV properties through inhibition of the large T antigen (Tag) helicase activity [11]. *In vitro*, fluoroquinolones not only reduce BKV DNA replication and the associated expression of viral proteins such as Tag but also lower the cell release of viral progeny by more than 90% [12]. Several studies have explored the efficacy of fluoroquinolones for the prevention and treatment of BKV-associated hemorrhagic cystitis after hematopoietic stem cell transplantation, which they found to be reasonably successful [13, 14]. On the other hand, a recently published multicenter, randomized, prospective trial utilizing a 30-day course of levofloxacin compared to placebo in kidney transplant recipients for the treatment of BK viremia found no improvement in BK viral load reduction or renal allograft function [15]. However, in this study the BKviremia found no improvement in BK viral load reduction and treatment with other adjuvant agents. The aim of our study was to retrospectively evaluate the effect of adding a 30-day course of ciprofloxacin to the treatment of persistent BKV infection in kidney transplant recipients who were refractory to immunosuppression reduction and treatment with other adjuvant agents.

2. Methods

2.1. Study Design and Patient Population. This is a single-center retrospective study of kidney transplant recipients with refractory BKV infection who received adjuvant therapy with ciprofloxacin 250 mg orally twice daily for 30 days. Patients were identified through a search of an electronic database of transplant recipients at UCSF Medical Center and had received a kidney transplant between July 2009 and June 2010. This time frame was selected as we collected information during those dates in a central database on all UCSF transplant recipients to evaluate our center specific BKV outcomes and treatment strategies. Refractory BKV infection was defined as persistently detectable viremia (≥500 copies/mL) and high grade viruria (≥10^6 copies/mL) despite immunosuppression reduction and the use of other adjuvant agents. This study was approved by our institutional review board as a retrospective analysis and informed consent was therefore not required. Outpatient and inpatient medical records were reviewed, including clinic visit notes, hospital notes, discharge summaries, and medication histories. Data obtained included patient demographics, transplant characteristics, laboratory and pathology results, and BKV urine and plasma PCR. The primary end-point was BKV plasma clearance, defined as an undetectable plasma viral load, 3 months after the initiation of ciprofloxacin. Secondary end-points included the percent reduction in BK viremia and the number of patients with >50% reduction in BK viremia 3 months after the initiation of ciprofloxacin as well as renal allograft function 3, 6, 9, and 12 months after the initiation of ciprofloxacin.

2.2. BKV Monitoring. The BKV screening protocol at our institution consists of monitoring quantitative BKV DNA PCR in urine and plasma at 1, 3, 6, 9, and 12 months after transplantation using the Focus 3M Integrated Cycler. Screening is considered positive at BK viruria ≥10^5 copies/mL and/or viremia ≥500 copies/mL. The diagnosis of BKVAN is made by a kidney allograft biopsy showing positive immunohistochemical staining for the SV-40 large T antigen with or without findings consistent with viral-mediated tubular epithelial cell damage and interstitial inflammation. Biopsies are performed at 6 months after transplantation for surveillance and at any other time for clinical indications such as elevated serum creatinine or persistently high BK viremia despite therapeutic interventions.

2.3. BKV Management. Our initial approach to BKV infection consists of a reduction in immunosuppression. The first step is a 50% decrease in the dose of the antimetabolite drug. Monthly BKV monitoring is performed until infection resolution, defined as undetectable BK viremia. If this goal is not achieved within 1–3 months, physicians may choose to further lower or discontinue the antimetabolite, lower the calcineurin inhibitor (CNI) trough goal, or switch from tacrolimus to cyclosporine. If a second round of immunosuppression reduction is not effective, adjuvant treatment with IVIG, cidofovir, leflunomide, and/or ciprofloxacin is considered.

3. Results

We identified 9 kidney transplant recipients with persistent BKV infection despite immunosuppression reduction, who subsequently received a 30-day course of ciprofloxacin. Baseline demographic and transplant characteristics of these recipients are summarized in Table 1. There were 5 men and 4 women. Seven received their kidney transplant from a deceased donor. Only 1 patient received a ureteral stent. All received antibody induction: rabbit thymoglobulin in 3 patients and basiliximab in 6 patients. Initial maintenance immunosuppression consisted of a CNI, mycophenolate mofetil (MMF), and prednisone in 7 of the 9 patients while the remaining 2 patients underwent early corticosteroid withdrawal and were maintained on only a CNI and MMF. One patient experienced an episode of antibody-mediated rejection which occurred prior to the BKV infection.

Median time to the first screen positivity of BKV infection was 95 days posttransplantation (range 31 to 224 days). Serum creatinine at the time of diagnosis ranged between 0.54 and 2.12 mg/dL. All patients had high-grade viruria and viremia at diagnosis. Management of immunosuppression and use of other antiviral therapies are summarized in Table 2. MMF had been reduced in all patients and then withdrawn completely in 6 of them. Leflunomide therapy replaced MMF in two of those in whom MMF was discontinued. Eight patients had received cidofovir and 4 had received IVIG prior to
| Table 1: Baseline characteristics. |
|----------------------------------|
| **Patient 1** | **Patient 2** | **Patient 3** | **Patient 4** | **Patient 5** | **Patient 6** | **Patient 7** | **Patient 8** | **Patient 9** |
| Age (years) | 66 | 49 | 49 | 74 | 62 | 27 | 43 | 71 | 55 |
| Sex | Female | Male | Male | Male | Female | Male | Female | Male | Female |
| Ethnicity | Asian | African American | African American | Caucasian | Hispanic | Asian | Asian | Hispanic | Asian |
| ESRD etiology | Hypertension | Hypertension | HIVAN | GN | Drug toxicity | GN | Lupus nephritis | Hypertension | Lupus nephritis |
| Number of kidney transplants | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Donor type | Deceased | Deceased | Deceased | Living unrelated | Deceased | Living related | Deceased | Deceased | Deceased |
| HLA mismatches | 6 | 5 | 5 | 3 | 5 | 2 | 4 | 6 | 6 |
| Stent at transplant | No | No | No | No | Yes | No | No | No | No |
| Induction immunosuppression | Basiliximab | rATG | Basiliximab | rATG | rATG | Basiliximab | Basiliximab | Basiliximab | Basiliximab |
| Maintenance immunosuppression | MMF, Tac | MMF, Tac, Prd | MMF, CsA, Prd | MMF, Tac, Prd | MMF, Tac, Prd | MMF, Tac, Prd | MMF, Tac, Prd | MMF, Tac | MMF, Tac, Prd |
| Acute rejection prior to BKV (treatment) | No | No | No | No | No | No | No | Yes (steroids) | No |

ESRD: end stage renal disease; HIVAN: human immunodeficiency virus associated nephropathy; GN: glomerulonephritis; HLA: human leukocyte antigen; rATG: rabbit antithymocyte globulin; DGF: delayed graft function; MMF: mycophenolate mofetil; Tac: tacrolimus; Prd: prednisone; CsA: cyclosporine.
Table 2: Management of BKV infection prior to addition of ciprofloxacin.

|                          | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 |
|--------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Time from transplant to BKV diagnosis (days) | 91        | 92        | 113       | 224       | 69        | 102       | 31        | 95        | 140       |
| SCr at diagnosis (mg/dL)  | 0.54      | 1.97      | 1.27      | 1.64      | 1.2       | 1.58      | 2.12      | 1.03      | 1.08      |
| Viremia at diagnosis (copies/mL) | 903       | 2 * 10^6  | 78500     | 45300     | 31900     | 36200     | 49400     | 10700     | 500       |
| Viruria at diagnosis (copies/mL) | 4600 * 10^6 | 4100 * 10^6 | 3000 * 10^6 | 1200 * 10^6 | 1700 * 10^6 | >500 * 10^6 | 116 * 10^6 | 170 * 10^6 | 5 * 10^6 |
| Immunosuppression management prior to ciprofloxacin | MMF reduction, Tac to CsA | MMF stopped | MMF stopped, CsA reduction | MMF reduction, Tac reduction | MMF stopped, Tac to CsA | MMF stopped | MMF stopped | MMF reduction, Tac reduction | MMF stopped |
| Cidofovir prior to ciprofloxacin | No        | Yes       | Yes       | Yes       | Yes       | Yes       | Yes       | Yes       | Yes       |
| Leflunomide prior to ciprofloxacin | No        | No        | No        | No        | Yes       | No        | No        | No        | Yes       |
| IVIG prior to ciprofloxacin  | No        | No        | Yes       | No        | Yes       | No        | No        | Yes       | Yes       |
| Time from BKV diagnosis to ciprofloxacin (days) | 59        | 77        | 130       | 217       | 175       | 199       | 91        | 65        | 379       |

Abbreviations: BKV: BK polyomavirus; SCr: serum creatinine; IVIG: intravenous immunoglobulin; BKVAN: BK virus associated nephropathy; MMF: mycophenolate mofetil; Tac: tacrolimus; CsA: cyclosporine A.
treatment and assessment periods. Ciprofloxacin 250 mg twice daily for 30 days was added to the other treatments at the physician’s discretion at a median of 130 days (range 59 to 379 days) following the diagnosis of BKV infection. All patients had persistent BK viremia at the time of initiation of ciprofloxacin. From the initial diagnosis of BK viremia to the start of ciprofloxacin, BK viremia had improved in 5 patients, worsened in 2 patients, and was unchanged in 2 patients.

All 9 patients underwent a renal allograft biopsy for cause after the BKV infection was diagnosed, and this demonstrated BKVAN in 7 of them. Ciprofloxacin was given before the diagnosis of BKVAN in 4 patients (range: 9–61 days; median 48 days) and after the diagnosis of BKVAN in 3 patients (range: 25–93 days; median 45 days). Three patients demonstrated complete resolution of viremia and another 3 had a decrease of more than 50% in plasma viral load at 3 months following the initiation of ciprofloxacin treatment (Table 3). Of the remaining 3 patients, 2 had an increase in the plasma viral load and 1 had a decrease of <50% at 3 months. The average reduction in viral load from the initiation of ciprofloxacin to month 3 was 58.8%. A higher percentage of patients who had a lower level of BK viremia from the time of initial diagnosis to starting ciprofloxacin had more than 50% reduction of BK viremia 3 months after ciprofloxacin (100%) compared to those patients with the same or higher level of BK viremia at the start of ciprofloxacin compared to the time of the initial diagnosis (25%; P = 0.48).

Overall, renal function remained relatively stable or improved in most patients after ciprofloxacin treatment with a mean serum creatinine of 1.67 ± 1.32 mg/dL at the initiation of ciprofloxacin compared to 1.61 ± 0.85 mg/dL one year after ciprofloxacin treatment (P = 0.84). However, serum creatinine rose significantly in patient 3 from 1.48 to 2.97 mg/dL (Figure 1). No allografts were lost due to BKV infection up to 1 year after the initiation of ciprofloxacin. There were no cases of tendonitis or tendon rupture, Clostridium difficile colitis, or ciprofloxacin-resistant infections during the ciprofloxacin treatment and assessment periods.

4. Discussion

BKV is a well-recognized infection in kidney transplant recipients, with known adverse effects on graft function and long-term graft survival. There is general consensus that immunosuppression reduction is the first line treatment for newly diagnosed BKV infection [8]. On the other hand, despite multiple published reports of different adjuvant therapies for refractory cases, a clear advantage of one drug or agent has yet to be demonstrated. In this report, we have described our experience with a novel treatment approach utilizing adjuvant ciprofloxacin for the management of persistent BKV infection in kidney transplant recipients who have failed to resolve the infection with alternative measures.

Our report shows that in a majority (67%) of patients with persistent BKV infection despite immunosuppression reduction, there was either a significant reduction or complete resolution of BK viremia after the addition of ciprofloxacin. At the same time, no adverse events of therapy such as tendonitis or Clostridium difficile colitis were noted. Additionally, no cases of fluoroquinolone-resistant urinary tract infections occurred in the follow-up period. Overall, renal function remained stable and no renal allografts were lost due to BKV infection within 1 year of the ciprofloxacin treatment. Ciprofloxacin treatment was well tolerated without any serious side effects in our small group of patients. Clinically, the fluoroquinolone antibiotics represent a convenient and relatively inexpensive class of medications that could treat persistent BKV infections with a low incidence of adverse events.

We readily acknowledge the limitations of our study. This is a descriptive case series with a small number of patients and retrospective data analysis. Since ciprofloxacin was used only in patients with persistent BKV infection, we could not examine the effect of this treatment as a de novo early therapy. In vitro evidence of the inhibitory effect of fluoroquinolones on BK viral replication has been previously demonstrated [11, 16]. Several studies have explored the efficacy of fluoroquinolones for the prevention and treatment of BKV-associated hemorrhagic cystitis after hematopoietic stem cell transplantation and found fluoroquinolones to be reasonably successful [13, 14]. In the hematopoietic stem cell transplant population, those who received 50 to 60 days of oral ciprofloxacin prophylaxis at 500 mg twice daily demonstrated a decrease in peak BK viruria early after transplantation (range: 7–39 days) and significantly lower rates of hemorrhagic cystitis [13, 14]. The data in the hematopoietic stem cell transplant population suggests that a higher dose of ciprofloxacin may be more effective than what was utilized in our study. A single published report utilizing fluoroquinolone treatment for de novo BKV infection in renal transplant recipients demonstrated clinical efficacy [17]. However, a recently reported randomized, double-blind clinical trial found that a
Table 3: Effect of ciprofloxacin on BKV infection.

|                      | Patient 1 | Patient 2       | Patient 3 | Patient 4       | Patient 5       | Patient 6       | Patient 7     | Patient 8       | Patient 9     |
|----------------------|-----------|------------------|-----------|------------------|------------------|------------------|---------------|------------------|---------------|
| Viruria (copies/mL)  | Before ciprofloxacin | 2 * 10^6 | 4600 * 10^6 | 110 * 10^6 | 14 * 10^6 | 1300 * 10^6 | >500 * 10^6 | 160 * 10^6 | 170 * 10^6 | 2 * 10^6 |
|                      | Month 3   | 1015            | 30 * 10^6 | 7 * 10^6         | 9 * 10^6         | 3100 * 10^6     | >500 * 10^6 | 357 * 10^6     | 330 * 10^6     | 44 * 10^6     |
|                      | Clearance | Yes             | >50%       | No               | No               | No               | No            | No               | No            |
| Viremia (copies/mL)  | Before ciprofloxacin | 830     | 500           | 5400            | 13700            | 63000            | 99300         | 8500           | 10700         | 500 |
|                      | Month 3   | 0               | 0           | 0                | 1600             | 167000          | 41100         | 4000           | 7300           | 3700 |
|                      | Clearance | Yes             | Yes         | Yes >50%         | No               | >50%             | No            | No               | No            |
| BKVAN                | Yes       | Yes             | Yes         | No               | Yes             | No               | Yes           | Yes             | Yes           |

BKV: BK polyomavirus; BKVAN: BK polyomavirus associated nephropathy.
30-day course of levofloxacin did not significantly improve BK viral load reduction or renal allograft function when used in addition to overall reduction of immunosuppression [15]. The patient population in this report differs from ours in one important regard: they received levofloxacin as the initial treatment for BKV infection, whereas our patients received ciprofloxacin after they had failed to clear BK viremia despite immunosuppression reduction and other adjuvant measures. Of note, in our series, we did not find a significant difference in treatment response between those who received ciprofloxacin early (<90 days after the diagnosis of BKV infection) and those who received it later.

Finally, the lack of a control group and the diversity of other anti-BKV therapies that patients had received previously made it difficult to isolate the specific effect of the ciprofloxacin treatment. This point is also noted in the fact that the most pronounced effect was seen with ciprofloxacin in patients who already had improving levels of BK viremia, making it difficult to separate out the effect of ciprofloxacin versus aggressive immunosuppression reduction. Additionally, when we examined the effect of ciprofloxacin by the stage of evolution of BK viremia prior to treatment, we found that a complete clearance of BK viremia at 3 months after treatment with ciprofloxacin was observed in 3 out of 5 patients with low but persistent (<10,000 copies/mL) BK viremia but in 0 out of 4 patients with high BK viremia (>10,000 copies/mL). One possibility is that a longer course of ciprofloxacin is needed to achieve a therapeutic response in this group of patients with high grade BK viremia.

5. Conclusions

Ciprofloxacin may be a useful therapeutic tool for BKV infection refractory to conventional treatment. Larger, randomized controlled trials are needed to demonstrate the exact clinical efficacy of ciprofloxacin and other fluoroquinolones in this group of patients. The optimal timing for initiation of treatment, the most efficacious dose and duration of antibiotic treatment, and the patient characteristics and viral subtypes that could potentially predict response to this form of treatment remain to be determined.

Conflict of Interests

The authors have no conflict of interests to report that relates to this paper.

Authors’ Contribution

David Arroyo participated in data collection and analysis as well as the writing of the paper; Sindhu Chandran and Parsia A. Vagefi participated in the data analysis and writing of the paper; David Wojciechowski participated in the research design, data analysis, and the writing of the paper.

Acknowledgment

David Arroyo would like to thank the Spanish Society of Nephrology for the Foreign Center Fellowship Grant.

References

[1] H. H. Hirsch, W. Knowles, M. Dickenmann et al., “Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients,” *The New England Journal of Medicine*, vol. 347, no. 7, pp. 488–496, 2002.

[2] D. C. Brennan, I. Agha, D. L. Bohl et al., “Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction,” *American Journal of Transplantation*, vol. 5, no. 3, pp. 582–594, 2005.

[3] D. Wojciechowski, R. Chanda, S. Chandran et al., “Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year,” *Transplantation*, vol. 94, no. 11, pp. 1117–1123, 2012.

[4] E. Ramos, C. B. Drachenberg, M. Portocarrero et al., “BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program,” *Clinical Transplants*, pp. 143–153, 2002.

[5] P. Sood, S. Senanayake, K. Sujeet et al., “Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study,” *Transplantation*, vol. 94, no. 8, pp. 814–821, 2012.

[6] H. M. Wadei, A. D. Rule, M. Lewin et al., “Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN),” *American Journal of Transplantation*, vol. 6, no. 5, part 1, pp. 1025–1032, 2006.

[7] R. M. Cannon, R. Ouseph, C. M. Jones, M. G. Hughes, M. Eng, and M. R. Marvin, “BK viral disease in renal transplantation,” *Current Opinion in Organ Transplantation*, vol. 16, no. 6, pp. 576–579, 2011.

[8] V. R. Dharnidharka, W. S. Cherikh, and K. C. Abbott, “An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States,” *Transplantation*, vol. 87, no. 7, pp. 1019–1026, 2009.

[9] E. R. Saad, B. A. Bresnahan, E. P. Cohen et al., “Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy,” *Transplantation*, vol. 85, no. 6, pp. 850–854, 2008.

[10] R. Hilton and C. Y. W. Tong, “Antiviral therapy for polyomavirus-associated nephropathy after renal transplantation,” *Journal of Antimicrobial Chemotherapy*, vol. 62, no. 5, pp. 855–859, 2008.

[11] M. Portolani, P. Pietrosemoli, C. Cermelli et al., “Suppression of BK virus replication and cytopathic effect by inhibitors of prokaryotic DNA gyrase,” *Antiviral Research*, vol. 9, no. 3, pp. 205–218, 1998.

[12] B. N. Sharma, R. Li, E. Bernhoff, T. J. Gutteberg, and C. H. Rinaldo, “Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells,” *Antiviral Research*, vol. 92, no. 1, pp. 115–123, 2011.

[13] A. Y. H. Leung, M. T. L. Chan, K.-Y. Yuen et al., “Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation,” *Clinical Infectious Diseases*, vol. 40, no. 4, pp. 528–537, 2005.
[14] A. N. Miller, A. Glode, K. R. Hogan et al., “Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients,” *Biology of Blood and Marrow Transplantation*, vol. 17, no. 8, pp. 1176–1181, 2011.

[15] B. T. Lee, S. Gabardi, M. Grafals et al., “Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial,” *Clinical Journal of the American Society of Nephrology*, vol. 9, no. 3, pp. 583–589, 2014.

[16] P. S. Randhawa, “Anti-BK virus activity of ciprofloxacin and related antibiotics,” *Clinical Infectious Diseases*, vol. 41, no. 9, pp. 1366–1367, 2005.

[17] A. Chandraker, S. Ali, C. B. Drachenberg et al., “Use of fluoroquinolones to treat BK infection in renal transplant recipients,” *American Journal of Transplantation*, vol. 4, supplement 8, 2004.